公开(公告)号：KR1020100056212A

公开(公告)日：2010-05-27

申请号：KR1020080115280

申请日：2008-11-19

Applicant: 국립암센터

Inventor： 김수열 ,  이창훈 ,  이병일 ,  정경채

IPC: A61K31/385 ,  A61K31/381 ,  A61P35/00

Abstract: PURPOSE: A transglutaminase inhibitor containing sulfarlem is provided to apply to a patient with abnormal transglutaminase overexpression and to suppress transglutaminase without side effects. CONSTITUTION: A pharmaceutical composition for preventing or treating diseases caused by transglutaminase activation contains sulfarlem or pharmaceutically acceptable salt thereof. The diseases are inflammatory diseases, cancers, or neurological disorders. The composition has anti-metastasis effect. The inflammatory diseases are chronic inflammatory disease such as degenerative arthritis, septicemia, or autoimmune myositis. The neurological disorders are Alzheimer diseases, Huntington disease, or Parkinson's disease.

Abstract translation: 目的：提供含有sulfarlem的转谷氨酰胺酶抑制剂以适用于转谷氨酰胺转氨酶异常反应的患者，并抑制转谷氨酰胺酶无副作用。 构成：用于预防或治疗由转谷氨酰胺酶活化引起的疾病的药物组合物含有磺胺类或其药学上可接受的盐。 疾病是炎性疾病，癌症或神经系统疾病。 该组合物具有抗转移作用。 炎性疾病是慢性炎症性疾病，如退行性关节炎，败血症或自身免疫性肌炎。 神经障碍是阿尔茨海默病，亨廷顿病或帕金森病。

公开(公告)号：KR100947209B1

公开(公告)日：2010-03-11

申请号：KR1020070098862

申请日：2007-10-01

Applicant: 국립암센터

Inventor： 김수열 ,  박강서 ,  정경채

IPC: A61K31/216 ,  A61P35/00

CPC classification number: A61K31/216

Abstract: 본 발명은 클로로겐산 또는 그 유도체를 포함하는 항암감작제에 관한 것으로, 보다 구체적으로는 항암제를 투여하여 암을 치료하는 경우 항암제의 효과를 높여주는 클로로겐산 또는 그 유도체를 포함하는 항암감작제에 관한 것이다. 또한, 본 발명은 클로로겐산 또는 그 유도체 및 약제학적으로 허용되는 담체를 포함하는 항암제 내성 저해용 조성물, 상기 조성물에 추가적으로 항암제를 포함하는 항암조성물 및 상기의 항암감작제를 투여하여 항암제내성을 극복하는 방법에 관한 것이다.
항암감작제, 클로로겐산, 항암제 내성

公开(公告)号：KR1020100011620A

公开(公告)日：2010-02-03

申请号：KR1020080072911

申请日：2008-07-25

Applicant: 국립암센터

Inventor： 김수열 ,  이창훈 ,  정경채 ,  이병일

IPC: A61K31/12 ,  A61P25/28

Abstract: PURPOSE: A composition containing curcumin for suppressing transglutaminase is provided to prevent and treat diseases induced by abnormal activity of the transglutaminase without side effects. CONSTITUTION: A pharmaceutical composition for preventing or treating neural diseases or inflammatory diseases caused by transglutaminase activation. The curcumin is denoted by chemical formula 1 and isolated from Curcuma longa L. Neural diseases is Alzheimer disease, multi-infarct dementia, hypothyrodism, alcoholic dementia, huntington disease or Parkinson's disease. Inflammatory diseases is degenerative arthritis, diabetes, autoimmunity myositis, arteriosclerosis, cerebral apoplexy, liver hardening, meningitis, inflammatory gastric ulcer, sinusitis, rhinitis, conjunctivitis, asthma, skin inflammatory disease, inflammatory bowel disease, rheumatic inflammation disease, and inflammatory collagen vascular disease.

Abstract translation: 目的：提供含有姜黄素抑制转谷氨酰胺酶的组合物，用于预防和治疗由转谷氨酰胺酶异常活动引起的疾病，无副作用。 构成：用于预防或治疗由转谷氨酰胺酶活化引起的神经疾病或炎性疾病的药物组合物。 姜黄素由化学式1表示，分离自姜黄L.神经疾病是阿尔茨海默病，多发性梗死性痴呆，甲状腺功能低下，酒精性痴呆，亨廷顿疾病或帕金森病。 炎性疾病是退行性关节炎，糖尿病，自身免疫性肌炎，动脉硬化，脑中风，肝硬化，脑膜炎，炎性胃溃疡，鼻窦炎，鼻炎，结膜炎，哮喘，皮肤炎性疾病，炎性肠病，风湿性炎症疾病和炎性胶原血管病 。

公开(公告)号：KR1020090033699A

公开(公告)日：2009-04-06

申请号：KR1020070098862

申请日：2007-10-01

Applicant: 국립암센터

Inventor： 김수열 ,  박강서 ,  정경채

IPC: A61K31/216 ,  A61P35/00

CPC classification number: A61K31/216

Abstract: A cancer sensitizer containing chlorogenic acid or derivative thereof is provided to show improved effects of cancer treatment and lower anti-cancer drug tolerance of cancer cells, thereby increasing sensitivity of the anti-cancer drug. A composition for inhibiting anti-cancer drug tolerance comprises chlorogenic acid or derivative thereof and a pharmaceutically allowable carrier. A composition for treating cancer contains the composition for inhibiting anti-cancer drug tolerance and anti-cancer drug. The anti-cancer drug is selected from the group consisting of mechloethamine, chlorambucil, phenylalanine, mustard, cyclophosphamide, ifosfamide, carmustine, lomustine, streptozotocin, busulfan, thiotepa, cisplatin, carboplatin, dactinomycin, doxorubicin, daunorubicin, idarubicin, mitoxantrone, plicamycin, mitomycin, C Bleomycin, vincristine, vinblastine, paclitaxel, docetaxel, etoposide, teniposide, topotecan and iridotecan.

Abstract translation: 提供含有绿原酸或其衍生物的癌症敏化剂，以显示癌症治疗的改善效果和较低的癌细胞的抗癌药物耐受性，从而增加抗癌药物的敏感性。 用于抑制抗癌药物耐受性的组合物包括绿原酸或其衍生物和药学上可允许的载体。 用于治疗癌症的组合物含有用于抑制抗癌药物耐受性和抗癌药物的组合物。 抗癌药选自甲氯胺素，苯丁酸氮芥，苯丙氨酸，芥子，环磷酰胺，异环磷酰胺，卡莫司汀，洛莫司汀，链脲霉素，白消安，噻替派，顺铂，卡铂，更生霉素，多柔比星，柔红霉素，伊达比星，米托蒽醌， 丝裂霉素，博来霉素，长春新碱，长春花碱，紫杉醇，多西他赛，依托泊苷，替尼泊苷，托泊替康和依立替康。

公开(公告)号：KR1020080108797A

公开(公告)日：2008-12-16

申请号：KR1020070056812

申请日：2007-06-11

Applicant: 국립암센터

Inventor： 김수열 ,  정경채

IPC: A61K31/353 ,  A61P25/00

CPC classification number: A61K31/353

Abstract: A pharmaceutical composition comprising a transglutaminase inhibitor containing EGCG(epigallocatechin gallate) is provided to cure the disease caused by the increment of transglutaminase activity. The transglutaminase inhibitor is comprised of the epigallocatechin gallate(EGCG) or its derivatives. The activity of transglutaminase is suppressed by using EGCG or its derivative. The pharmaceutical composition for treating the disease caused by the increment of transglutaminase activity comprises the epigallocatechin gallate(EGCG) or its derivatives, wherein the disease is nervous system disorders including Alzheimer's disease, Huntington's disease and Parkinson's disease or cancer.

Abstract translation: 提供包含含有EGCG（表儿儿茶素没食子酸酯）的转谷氨酰胺酶抑制剂的药物组合物以治愈由转谷氨酰胺酶活性增加引起的疾病。 转谷氨酰胺酶抑制剂由表没食子儿茶素没食子酸酯（EGCG）或其衍生物组成。 通过使用EGCG或其衍生物抑制转谷氨酰胺酶的活性。 用于治疗由转谷氨酰胺酶活性增加引起的疾病的药物组合物包括表没食子儿茶素没食子酸酯（EGCG）或其衍生物，其中疾病是神经系统疾病，包括阿尔茨海默病，亨廷顿病和帕金森病或癌症。